# Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

> **NCT05645536** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Tolmar Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** TOL2506
- **DRUG:** Tamoxifen
- **DRUG:** Letrozole tablets
- **DRUG:** Anastrozole Tablets
- **DRUG:** Exemestane Tablets

## Key facts

- **NCT ID:** NCT05645536
- **Lead sponsor:** Tolmar Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-12-28
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05645536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05645536, "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05645536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*